Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

Dr. Raza Bokhari, Executive Chairman & CEO of Medicus will deliver a company presentation as Medicus enters 2026 with multiple Phase 2 Catalysts across clinical, regulatory, and pipeline expansion ...

Kv7.2/7.3 channels are voltage-gated potassium channels involved in regulating membrane potential and neuronal excitability.

Detailed price information for Medicus Pharma Ltd (MDCX-Q) from The Globe and Mail including charting and trades.

This is a summary of: Liu. H. et al. Viral RNA blocks circularization to evade host codon usage control. Nature https://doi.org/10.1038/s41586-025-09809-y (2025).

French newspaper La Lettre said the Paris-based biotech – which is listed on the Nasdaq – has been on Lilly's radar after ...

Cell division is an essential process for all life on Earth, yet the exact mechanisms by which cells divide during early ...

The U.S. Senate Permanent Subcommittee on Investigations held a high-profile hearing titled 'The Corruption of Science and ...

Jeremy has more than 2200 published articles on Collider to his name, and has been writing for the site since February 2022. He's an omnivore when it comes to his movie-watching diet, so will gladly ...

In a groundbreaking development that could revolutionise cancer treatment, researchers have advanced an mRNA-based vaccine ...